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ABSTRACT
Plasma cell-free DNA (cfDNA) is a small DNA fragment circulating in the 
bloodstream originating from both non-tumor- and tumor-derived cells. A previous 
study showed that a plasma telomeric cfDNA level decreases in sporadic breast cancer 
patients compared to controls. Tumor suppressor gene products including BRCA1 and 
BRCA2 (BRCA1&2) play an important role in telomere maintenance. In this study, we 
hypothesized that the plasma telomeric cfDNA level is associated with the mutation 
status of BRCA1&2 genes. To test this hypothesis, we performed plasma telomeric 
cfDNA quantitative PCR (qPCR)-based assays to compare 28 women carriers of the 
BRCA1&2 mutation with age-matched controls of 28 healthy women. The results 
showed that the plasma telomeric cfDNA level was lower in unaffected BRCA1&2 
mutation carriers than in age-matched controls from non-obese women (BMI < 30), 
while there was no association between unaffected BRCA1&2 mutation carriers and 
age-matched controls in obese women (BMI > 30). Moreover, the plasma telomeric 
cfDNA level applied aptly to the Tyrer-Cuzick model in non-obese women. These 
findings suggest that circulating cfDNA may detect dysfunctional telomeres derived 
from cells with BRCA1&2 mutations and, therefore, its level is associated with breast 
cancer susceptibility. This pilot study warrants further investigation to elucidate the 
implication of plasma telomeric cfDNA levels in relation to cancer and obesity.
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INTRODUCTION
Plasma, serum, and other biofluids contain very 
low amounts of circulating extracellular cell-free DNA, 
also called cfDNA. cfDNA has become an increasingly 
important source for the development of liquid biopsy 
assays for early cancer detection. Indeed, it has been 
shown that cancer patients present both normal tissue- 
and tumor-derived cfDNA in the bloodstream [1]. Current 
cfDNA assays have mostly focused on monitoring 
cancer-specific mutations or methylation changes by 
targeting cell-free tumor DNA (ctDNA) [2]. In this case, 
the assays require prior information on specific genetic 
or epigenetic alterations present in the original tumor 
lesion. In order to detect cfDNA alterations associated 
with breast cancer initiation (where the amount of affected 
DNA is significantly low), the assays require sufficient 
improvement in the sensitivity of the assay, making this 
research area quite challenging [3, 4].
We recently devised a qPCR-based cfDNA assay to 
measure telomeric cfDNA levels (i.e., relative amounts 
of [TTAGGG]n sequences) in plasma. Using this assay, 
we reported that plasma telomeric cfDNA levels were 
significantly decreased in sporadic breast cancer patients 
                        Research Paper
Oncotarget4215www.impactjournals.com/oncotarget
with no prior treatment, compared to non-cancer controls 
[5]. While a plasma centromeric cfDNA level was 
also measured in the study and the difference between 
breast cancer patients and controls was also statistically 
significant, the actual effect size was modest between 
breast cancer patients and controls [5]. These results 
indicate that changes in telomeric cfDNA levels could 
be more constructive as a biomarker than changes in 
centromeric cfDNA levels during breast carcinogenesis. 
Furthermore, we found that the plasma telomeric cfDNA 
level in women with advanced breast tumors (stages II–III) 
was lower than those at earlier stages of breast cancer 
(stages 0–I) [5]. These findings suggest that telomere 
dysfunction (e.g., rapid telomere shortening) in body 
tissues might accumulate during cancer development 
and be associated with cancer progression, resulting in 
dynamic changes in the plasma telomeric cfDNA level.
Two major factors responsible for telomere length 
shortening are cellular replicative aging and genetics. 
BRCA1 and BRCA2 (BRCA1&2) are multifunctional 
proteins and maintain genomic stability by regulating 
DNA repair, transcription, and cell cycle in response 
to DNA damage [6, 7]. Several studies suggest that 
BRCA1&2 haploinsufficiency could involve defects in 
telomere maintenance [8–10]. Because BRCA1&2 gene 
mutation carriers have a high risk of developing early-
onset breast and ovarian cancer during their lifetime, the 
aim of this study is to determine whether plasma telomeric 
cfDNA level is associated with the BRCA1&2 mutations. 
This pilot study provides important supportive evidence 
for ensuring further research to determine the potential 
value of the plasma telomeric cfDNA level in predicting 
cancer development and cancer risk.
RESULTS
We hypothesized that a circulating telomeric cfDNA 
level could be affected by BRCA1&2 heterozygous 
mutations; consequently, the telomeric cfDNA level 
decreases in BRCA1&2 mutation carriers as compared 
to healthy controls. In order to avoid reverse causation, 
we tested this hypothesis only in unaffected women. We 
analyzed plasma samples from 56 individuals, including 
28 unaffected women carrying either a BRCA1 mutation 
(n = 16), a BRCA2 mutation (n = 9), or both BRCA1 and 
BRCA2 mutations (n = 3), and 28 age-matched healthy 
controls. The age range was from 23 to 74. Demographic 
and clinical characteristics of both cases and controls 
are provided in Table 1 and Supplementary Table 1, 
respectively. Telomeric cfDNA qPCR assay was performed 
as previously described with minor modifications [5]. 
Both parametric and non-parametric tests were employed 
to compare the telomeric cfDNA qPCR results collected 
from the two groups (carriers and controls). We first 
used paired t-test to compare the results between age-
matched BRCA1&2 carriers vs. control women, thereby 
eliminating the confounding factor of age. Overall, there 
was no difference of the telomeric cfDNA level between 
BRCA1&2 carriers and controls (p = 0.0774, d = 0.351). 
However, upon subgrouping the samples by BMI, the 
plasma telomeric cfDNA level was significantly lower in 
BRCA1&2 carriers than those in age-matched controls in 
the non-obese group (n = 14 pairs, p = 0.0253, d = 0.691) 
(Figure 1A). In contrast, there was no difference in the 
telomeric cfDNA level between BRCA1&2 carriers and 
age-matched controls in the obese group (n = 14 pairs, 
p = 0.8991, d = 0.036) (Figure 1B). Wilcoxon signed-rank 
test showed that the p-value was also significant when 
BRCA1&2 carriers were compared with age-matched 
controls in the non-obese group (p = 0.0257), while the 
p-value was 0.976 in the obese group (Figure 1B). The 
effect size (difference) between BRCA1&2 carriers and 
age-matched controls in the non-obese group was a range 
from medium to large (d = 0.691). We also measured 
relative telomere length by qPCR in matched peripheral 
blood DNA samples as several reports have shown 
BRCA1&2 carriers having relatively shorter telomeres in 
leukocytes as compared to healthy controls [10, 11]. Our 
analyses using paired t-test showed that leukocyte telomere 
length was significantly shorter in BRCA1&2 carriers 
than those in age-matched controls in the non-obese group 
(p = 0.0320, d = 0.666) but not in the obese group (p = 0.8203, 
d = 0.064) (Figure 1C and 1D). However, there was no 
association between the plasma telomeric cfDNA level (T/L 
copy ratio) and leukocyte telomere length (T/S ratio) in this 
study population (Supplementary Figure 1), supporting our 
previous findings that leukocyte DNA is not a major source 
of cfDNA production [5].
To further evaluate our results with other method, 
we used the Tyrer-Cuzick model that is a well-studied, 
widely available model for predicting breast cancer risk 
[12, 13]. We hypothesized that either telomeric cfDNA 
level or telomere length or both fit with the Tyrer-Cuzick 
model in non-obese women, thus acting as potential 
biomarker(s) for breast cancer development. When 
individual risk of developing breast cancer within 10 years 
was calculated and the plasma telomeric cfDNA level 
was compared with the 10-year risk, we found that the 
telomeric cfDNA level was inversely correlated with the 
10-year risk (p = 0.00675, r2 = 0.2007), while the telomere 
length results were not significantly correlated with the 
10-year risk (p = 0.1363, r2 = 0.0083) (Figure 2). Only 
when the data was analyzed in the non-obese controls 
(the 10-year risk < 5%, n = 22), the telomere length 
results were correlated with the 10-year risk (p = 0.0161, 
r2 = 0.2565). This significant correlation is likely attributed 
to age because the age factor is strongly associated with 
the 10-year risk score especially when the risk is less than 
5% (Supplementary Figure 2).
Our findings indicate that obesity might have an effect 
on plasma telomere cfDNA level or/and leukocyte telomere 
length. Therefore, we next compared the difference in the 
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plasma telomeric cfDNA level among 19 age-matched low 
(< 30) and high (> 30) BMI healthy control pairs. Non-
parametric Wilcoxon signed-rank test was employed and 
showed that a lower plasma telomeric cfDNA level was 
associated with obesity (BMI > 30) in healthy individuals 
(p = 0.00034, d = 1.0667) (Figure 3A, Supplementary Table 2). 
In contrast, we did not find the difference in leukocyte 
telomere length between the obese and the non-obese 
groups (p = 0.093, d = 0.421) (Figure 3B, Supplementary 
Table 2), suggesting that obesity (based on BMI) is not a 
strong modifier of telomere length [14, 15].
DISCUSSION
This pilot study is the first to determine the 
association of the plasma telomeric cfDNA level with 
genetic risk in unaffected women with and without 
mutations in BRCA1 or/and BRCA2 genes. The findings 
suggest that circulating plasma telomeric cfDNA levels 
are affected by BRCA1&2 heterozygous mutations in non-
obese women. Until now, conflicting studies report the 
correlation between shorter telomere length in leukocyte-
derived DNA and BRCA1&2 mutation status. Our results 
Table 1: Demographic and clinical characteristics, telomeric cfDNA level, and telomere length of BRCA1&2 carrier 
women
Sample ID Age Race BMI
Current 
smoking 
status
Menstrual 
Status
Mutation 
Status
10-year 
risk
Telomeric 
cfDNA level
(± S.E.)
Relative 
telomere length 
(± S.E.)
BR02-469 23 White 27.3 No Pre BRCA1 4.9% 0.176 (± 0.0039) 1.97 (± 0.080)
BR27-689 23 White 32.1 No Pre BRCA2 5.7% 0.169 (± 0.0044) 2.39 (± 0.093)
BR12-497 24 White 28.5 No Pre BRCA1 8.6% 0.114 (± 0.0071) 1.70 (± 0.104)
BR31-071 24 White 24.3 No Pre BRCA1 19.0% 0.131 (±0.0009) 2.14 (± 0.084)
BR03-560 29 White 27.3 No Pre BRCA1 26.3% 0.146 (± 0.0079) 1.60 (± 0.095)
BR05-977 32 White 26.2 No Pre BRCA2 19.4% 0.247 (± 0.0621) 0.97 (± 0.054)
BR24-030 34 White 32.0 No Pre BRCA1 66.7% 0.038 (±0.0055) 2.00 (± 0.167)
BR07-177 37 White 33.9 No Post BRCA1 & 
BRCA2
18.8% 0.079 (± 0.0064) 1.70 (± 0.049)
BR34-032 37 White 21.1 No Pre BRCA2 16.1% 0.154 (± 0.0067) 2.08 (± 0.151)
BR11-468 38 White 27.3 Yes Pre BRCA1 23.8% 0.158 (± 0.0077) 2.24 (± 0.130)
BR14-590 39 White 32.8 No Pre BRCA2 18.8% 0.105 (± 0.0091) 1.87 (± 0.136)
BR35-034 41 White 31.6 No pre BRCA1 30.1% 0.159 (± 0.0079) 2.33 (± 0.070)
BR06-978 42 White 19.1 No Post BRCA2 17.2% 0.042 (± 0.0050) 1.76 (± 0.032)
BR13-588 45 White 31.2 No Post BRCA2 22.8% 0.090 (± 0.0071) 1.79 (± 0.067)
BR26-158 45 White 39.4 No n/a BRCA1 33.7% 0.214 (± 0.0175) 1.61 (± 0.093)
BR01-938 46 White 22.7 No Post BRCA1 32.8% 0.074 (± 0.0048) 1.76 (± 0.110)
BR28-925 46 White 32.1 No Pre BRCA2 21.5% 0.147 (± 0.0046) 1.48 (± 0.059)
BR16-766 47 White 35.7 No Post BRCA1 34.9% 0.171 (± 0.0185) 1.54 (± 0.110)
BR20-204 48 White 25.8 No Post BRCA1 19.9% 0.080 (± 0.0032) 2.14 (± 0.121)
BR32-664 49 White 32.6 No Post BRCA1 28.4% 0.126 (± 0.0026) 2.00 (± 0.068)
BR04-976 50 White 26.6 No Pre BRCA2 22.8% 0.131 (± 0.0074) 0.81 (± 0.022)
BR30-175 51 White 35.4 No Post BRCA1 26.3% 0.090 (± 0.0029) 1.39 (± 0.036)
BR29-168 53 White 32.2 No Post BRCA1 26.9% 0.142 (± 0.0086) 1.59 (± 0.039)
BR36-383 56 White 29.3 No Post BRCA1 & 
BRCA2
28.2% 0.108 (± 0.0063) 1.47 (± 0.111)
BR19-102 61 White 37.3 No Post BRCA1 & 
BRCA2
27.9% 0.025 (± 0.0014) 1.46 (± 0.061)
BR33-750 66 White 27.1 No Post BRCA1 12.6% 0.195 (± 0.0054) 1.57 (± 0.152)
BR21-207 70 White 22.6 No Post BRCA2 29.5% 0.133 (± 0.0163) 1.65 (± 0.142)
BR17-822 74 White 33.5 No Post BRCA1 8.5% 0.060 (± 0.0071) 1.58 (± 0.065)
*S.E., standard error of the mean.
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Figure 1: Non-obese women with BRCA1&2 gene mutation have a lower plasma telomeric cfDNA level and shorter 
leukocyte telomere length. (A) The telomeric cfDNA level was plotted using 14 age-matched pairs from non-obese women (BMI < 30). 
Mean (± S.D.) of the telomeric cfDNA level was 0.191 (± 0.073) in controls and 0.135 (± 0.050) in BRCA1&2 carriers. 71.4% (10 of 
14 pairs) show a reduction in the telomeric cfDNA level in BRCA1&2 carries. (B) The telomeric cfDNA level was plotted using 14 age-
matched pairs from obese women (BMI > 30). Mean (± S.D.) of the telomeric cfDNA level was 0.115 (± 0.040) in controls and 0.113 
(± 0.053) in BRCA1&2 carriers. 50.0% (7 of 14 pairs) show a reduction in the telomeric cfDNA level in BRCA1&2 carries. (C) Relative 
telomere length was plotted using the same pairs from non-obese in (A). Mean (± S.D.) of telomeric cfDNA level was 1.85 (± 0.45) in 
controls and 1.69 (± 0.41) in BRCA1&2 carriers. 71.4% (10 of 14 pairs) show a reduction in the telomeric cfDNA level in BRCA1&2 
carries. (D) Relative telomere length was plotted using the same pairs from obese women in (B). Mean (± S.D.) of telomeric cfDNA level 
was 1.79 (± 0.37) in controls and 1.77 (± 0.30) in BRCA1&2 carriers. 64.2% (9 of 14 pairs) show a reduction in the telomeric cfDNA level 
in BRCA1&2 carries. All p values were shown based on paired Student’s t test.
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confirmed that leukocyte telomere length was affected by 
BRCA1&2 heterozygous mutations in non-obese women 
(but not in obese women). Furthermore, it is noteworthy 
that there is a significant correlation between the telomeric 
cfDNA level and the Tyrer-Cuzick 10-year risk score of 
developing breast cancer. These findings support our 
hypothesis that the telomeric cfDNA level could be a 
biologically-relevant quantitative biomarker for breast 
cancer development.
Although the underlying molecular mechanism of 
alteration in the plasma telomeric cfDNA level remains 
unclear, several studies reported that epithelial breast cells 
possess enhanced proliferative potential in women with 
BRCA1&2 haploinsufficiency [16–18]. We speculate 
that after the occurrence of “one-hit” of BRCA1&2 gene, 
the remaining wild-type allele of BRCA1&2 may not be 
sufficient to recover the deficiency in DNA repair and/
or replication properly at the telomeres in target somatic 
tissues. Consequently, a telomere shortening rate in 
cells of BRCA1&2 carriers could be accelerated during 
development and aging, compared to controls [19]. 
Thus, we speculate that the circulating telomeric cfDNA 
level could reflect the somatic and dynamic changes in 
telomere dysfunction in target tissue cells; as a result, we 
Figure 2: The plasma telomeric cfDNA level is correlated with individual 10-year breast cancer risk in non-obese 
women. (A) Comparison between the plasma telomeric cfDNA level and the 10-year risk in non-obese women (n = 28). (B) Comparison 
between relative leukocyte telomere length and the 10-year risk in non-obese women (n = 28).
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observed that BRCA1&2 carriers have relatively lower 
telomeric cfDNA level than controls, even before a total 
loss of the remaining wild-type allele occurs and cancer 
appears. Moreover, we demonstrated that a lower plasma 
telomeric cfDNA level was associated with a higher BMI. 
The question of why the plasma telomeric cfDNA level 
is lower in obese women requires further investigation; 
however, we pose the following two possible explanations. 
First, adipocyte cells may have relatively shorter telomeres 
[20], and therefore increased death of the adipocyte cells 
results in a lower telomeric cfDNA level in plasma. 
Alternatively, obesity-related metabolic changes may 
induce higher enzymatic activity (e.g., nuclease) in the 
bloodstream that in turn facilitate degradation of cfDNA 
fragments outside-in [21]. Therefore, it is of value to 
further studying the implications of plasma telomeric 
cfDNA levels in cancer development and obesity.
Because we only included Caucasian women, these 
findings may not be generalized to men and/or other 
ethnicities. In addition, because the sample size in this 
study was limited, we were not able to identify differences 
in the plasma telomeric cfDNA level between BRCA1 
carriers, BRCA2 carriers, and dual carriers. This study 
also lacks information about the specific mutation site(s) 
on BRCA1&2 genes. Investigating the correlation of the 
changes in the plasma telomeric cfDNA level with specific 
BRCA1&2 mutation sites may provide new insights into 
risk assessments of breast cancer.
In summary, we found that BRCA1&2 heterozygous 
mutations altered the plasma telomeric cfDNA level in 
non-obese women. This work highlights that the plasma 
telomeric cfDNA level may reflect the dynamic changes 
occurring in the telomeres of the somatic tissue cells 
as a result of genetic predisposition (i.e., BRCA1&2 
mutations). The next steps would be to replicate the 
findings in a larger study. It is also critical to examine the 
prospective associations between the plasma telomeric 
cfDNA level, predictive risk factors for breast cancer, and 
breast cancer occurrence, and also to further determine 
whether the plasma telomeric cfDNA level mediates the 
association between these risk factors and breast cancer.
MATERIALS AND METHODS
Human specimens
Paired leukocyte DNA and frozen plasma samples 
were collected from BRCA1&2 mutation carriers 
(n = 28, 23 ≤ age ≤ 74, mean age = 46) and their age-
matched controls (n = 28, ± 1 year) by the Susan G. Komen 
Figure 3: Healthy obese women have a lower telomeric cfDNA level than healthy non-obese women. (A) The telomeric 
cfDNA level was sub-grouped by BMI using age-matched control women (n = 19 pairs). Mean (± S.D.) of the telomeric cfDNA level was 
0.217 (± 0.084) in the BMI < 30 group and 0.105 (± 0.046) in the BMI > 30 group. 84.2% (16 of 19 pairs) show a reduction in the telomeric 
cfDNA level in the BMI > 30 group. (B) Relative telomere length was sub-grouped by BMI using age-matched control women (n = 19 
pairs). Mean (± S.D.) of telomere length was 1.67 (± 0.35) in the BMI < 30 group and 1.83 (± 0.34) in the BMI > 30 group. There is no 
difference of telomere length between two groups. All p values were shown based on Wilcoxon signed-rank test.
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Tissue Bank at Indiana University Simon Cancer Center 
(KTB) with an approved Indiana University Institutional 
Review Board protocol. All samples were collected in 
accordance with standard operating procedures described 
on the KTB website and with donor’s written informed 
consent. All BRCA1&2 carrier cases and healthy 
controls were unaffected women. Of note, the BRCA1&2 
mutation status of controls was based on self-reported 
information. The demographical and clinical information 
of the study subjects were collected by the KTB through 
a baseline questionnaire, and were shown in Table 1 and 
Supplementary Table 1. Body Mass Index (BMI) was 
calculated as weight divided by squared height. 
Plasma cfDNA extraction
Frozen plasma samples were thawed on ice prior to 
cfDNA isolation and centrifuged for 3 min at ≥ 11,000 × g 
in order to remove residual cells, cell debris, and particulate 
matter. A sodium Iodide (NaI)-based method was used 
for each cfDNA extraction as described previously [5]. 
cfDNA concentrations were measured using Quant-iT™ 
PicoGreen™ dsDNA Reagent (Thermo Fisher Scientific). 
The fluorescence intensity was measured with a Synergy 2 
Multi-Mode Reader at emission wavelength of 520 nm and 
excitation wavelength of 480 nm.
Telomeric cfDNA qPCR assay
Telomeric cfDNA levels were measured by qPCR as 
described previously except for some minor modifications 
[5]. The qPCR was performed on QuantStudio 6 Flex 
Real-Time PCR System (Thermo Fisher Scientific) in 
10 μL volume of PCR reaction with 1× SYBR Select 
(Thermo Fisher Scientific), primers, and cfDNA (~50 pg) 
as template. The primer sequences are shown in 
Supplementary Table 3. The thermal cycling profile is 
Stage 1 for 2 min at 95°C; Stage 2 for 2 cycles of 15 s at 
94°C, 15 s at 49°C; and Stage 3 for 40 cycles of 15 s at 
94°C, 15 s at 60°C, 20 s at 72°C. The qPCR results were 
analyzed based on plasmid DNA standard curves. The 
plasmid DNA contains (TTAGGG)
13
 and 121 bp of LINE 
(Long INterspersed Element) nucleotide sequences. Five 
concentrations of a plasmid DNA sample were prepared 
by five serial dilutions (3.62 × 109 to 5.79 × 106 copies). 
To monitor and compensate for inter-plate variations in 
PCR efficiency, each plate included standard plasmid 
DNAs as well as reference DNA (Promega, G152A). All 
experimental DNA samples were repeated at least three 
times in duplicate. All samples have a standard deviation 
of less than 0.5 for the threshold cycle (Ct) values. The 
inter- and intra-assay coefficients of variations (CVs) were 
13.0% and 3.9%, respectively. Melting curve analysis was 
performed on every run to verify specificity and identity 
of the PCR products. The telomeric cfDNA levels were 
presented as T/L copy ratios (= telomere copy number/ 
Line copy number) calculated from the average of more 
than three independent experiments.
Leukocyte DNA extraction
Paired leukocyte DNAs along with plasma 
from both case and control women were obtained as a 
lyophilized power after the Komen Tissue Bank was 
extracted from whole blood samples using the Flex Star 
automated system with the AGFStar Fresh WB Extraction 
Kit (Autogen). The DNA was rehydrated with UltraPure 
DNase/RNase-free water (Thermo Fisher Scientific, 
10977015). The DNA concentration was quantitated 
by Nanodrop 2000 spectrophotometer (Thermo Fisher 
Scientific).
Relative telomere length measurement
Singleplex telomere length qPCR was performed 
with a QuantStudio 6 Flex Real-Time PCR System and 
analyzed as described previously [5, 22, 23]. The qPCR 
was performed on QuantStudio 6 Flex Real-Time PCR 
System (Thermo Fisher Scientific) in 10 μL volume of 
PCR reaction with 1× SYBR Select (Thermo Fisher 
Scientific), primers, and DNA as template. The telomere 
primers (telg and telc) and β-globin gene primers (hbgu 
and hbgd) were used for this assay. Each DNA standard 
curve was generated using a pooled female genomic DNA 
(Promega, G152A) and used for calculation of the T/S 
ratios (= ratios of “telomere quantities/single copy gene 
quantities”). All experimental DNA samples were repeated 
at least three times in duplicate. All replicate samples had 
a standard deviation of less than 0.5 for the threshold cycle 
(Ct) values.
Breast cancer risk assessment
The Tyrer-Cuzick (or International Breast 
Intervention Study, IBIS) model was used to estimate a 
woman’s risk of developing breast cancer within the next 
10 years using information about BRCA1/2 mutation 
carrier status and other risk factors including family 
history of breast and ovarian cancer, age at menarche, 
parity, age at first childbirth, age at menopause, atypical 
hyperplasia, lobular carcinoma in situ, height, and body 
mass index. The risk factors were entered into the model 
using the freely available software IBIS_RiskEvaluator_
v8b (www.ems-trials.org/riskevaluator) [12, 13].
Statistical analysis
Shapiro-Wilk test was used to test for normality in 
each group. Student’s t test (parametric) and Wilcoxon 
signed-rank test (non-parametric) were performed to test 
the association between a telomeric cfDNA level and 
breast cancer risk factors (BRCA1&2 mutations, BMI). 
Cohen’s d was used to calculate the effect size for paired 
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two-sample t test using WebPower (http://webpower.
psychstat.org) [24]. Linear regression analysis was used 
to examine the correlation between the plasma telomeric 
cfDNA level and leukocyte telomere length, as well as 
between the 10-year risk and either the plasma telomeric 
cfDNA level or leukocyte telomere length. R squared (r2) 
was used for assessing the fit of the regression line. Two-
tailed p values of less than 0.05 were considered to be 
statistically significant. 
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